Expert Interview
Examining the potential of Evkeeza (evinacumab) as a new treatment option for patients with Homozygous Familial Hypercholesterolemia (HoFH)
Ticker(s): REGN, RAREInstitution: Imperial College London
Dr Kausik Kumar Ray - MD (Imperial College London)
- Professor of Public Health, Department of Public Health and Primary Care, School of Public Health, Imperial College London.
- Very comfortable discussing the standard of care for Homozygous Familial Hypercholesterolemia (HoFH) and is familiar with the published literature on Evkeeza (evinacumab)?
- Led the development of inclisiran for 7 years the first siRNA therapy among others
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
